Evidence map›Paper›PMID 33480830›Full record

ArticleLeukemia & lymphoma2021

The impact of cell-of-origin, MYC/Bcl-2 dual expression and

Alexander Augustyn, L Jeffrey Medeiros, Ethan B Ludmir, Jillian Gunther, Penny Fang, Shaoying Li, Chi Young Ok, Mikaela E Bankston, Vivek Verma, Dario Pasalic and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. High-grade B-cell lymphomas: high difficulties to diagnose and treat?Hematology. American Society of Hematology. Education Program · 2025
    Review
  2. Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Review
  3. Review
  4. Prognostic value ofQuantitative imaging in medicine and surgery · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Alexander AugustynDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L Jeffrey MedeirosDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ethan B LudmirDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5472-5344
Jillian GuntherDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Penny FangDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shaoying LiDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chi Young OkDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mikaela E BankstonDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vivek VermaDepartment of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA.
Dario PasalicDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sairah AhmedDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Loretta J NastoupilDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason R WestinDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1824-2337
Paolo StratiDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7445-1459
Sattva S NeelapuDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ranjit NairDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Raphael E SteinerDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3717-3629
Swaminathan P IyerDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alma RodriguezDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luis E FayadDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher R FlowersDepartments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bouthaina S DabajaDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chelsea C PinnixDepartments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3982-3664
The University of Texas MD Anderson Cancer Center · USAllegheny General Hospital · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated

Indexed as

Lymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-mycAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinHumansNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6CyclophosphamideDoxorubicinProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycBCL2consolidative radiationdiffuse large B-cell lymphomaimmunophenotypeLymphomaMYC

Identifiers

PMID33480830
PMCPMC8262455
OpenAlexW3125956093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.